Finoriq research workspace
ALUMIS INC. (ALMS) Insider Transactions & Form 4 Activity
Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for ALUMIS INC. (ALMS).
Company Snapshot
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
- Company
- ALUMIS INC. (ALMS)
- Ticker
- ALMS
- Market Cap
- $3.6B
- Latest Price
- $28.3
- Industry
- Biotech & Pharma
ALUMIS INC. (ALMS) Recent Insider Transactions
Recent market insider transaction records indexed for ALUMIS INC. (ALMS).
| Insider | Code | Value | Transaction Date |
|---|---|---|---|
| AKKARAJU SRINIVASCommon Stock | P | Acquired | $10M | 2026-01-09 |
| Foresite Labs, LLCCommon Stock | P | Acquired | $2M | 2026-01-08 |
| Foresite Labs, LLCCommon Stock | P | Acquired | $5M | 2026-01-08 |
| Foresite Labs Affiliates 2021, LLCCommon Stock | P | Acquired | $2M | 2026-01-08 |
| Foresite Labs Affiliates 2021, LLCCommon Stock | P | Acquired | $5M | 2026-01-08 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.